1. Novartis CEO Joe Jimenez said the company’s eye-care business, Alcon, expects single-digit growth in 2017, altering the drugmaker’s earlier forecast that sales would remain flat. (Bloomberg)
2. Dublin-based UDG Healthcare acquired Cambridge BioMarketing for up to $35 million to increase its capabilities in patient communications for orphan and rare disease drugs in the U.S. It follows the $32 million acquisition of Philadelphia-based healthcare group Vynamic last week.
3. Spark Therapeutics received priority review for retinal gene therapy Luxturna. If approved, it would be thefirst FDA-approved gene therapy in the U.S. (Endpoints News)
4. Novo Nordisk U.S. president Jesper Høiland replaced Bob Ward as CEO and president of Radius Health. Høiland will lead the launch of Radius’ osteoporosis drug. (Endpoints News)
5. Johnson & Johnson raised its 2017 revenue forecast to up to $76.1 billion, driven by new product approvals and acquisitions such as the $30 billion purchase of Swiss drugmaker Actelion in June. (U.S. News & World Report)